The Afirma Thyroid FNA Analysis gives your doctor a clinically proven way to get the full story about your thyroid nodule. More complete information helps patients avoid unnecessary surgeries, cost and anxiety.

Step 1: FNA Biopsy
Your physician will collect thyroid nodule cells with a very thin needle (FNA biopsy) for both cytopathology assessment and possible genomic evaluation. Collecting multiple samples at one time will allow you to avoid returning for a second procedure.
Step 2: Cytopathology
Your thyroid nodule cells are then viewed by a cytopathologist—a doctor trained to examine cells under a microscope. If the result is benign or malignant, Afirma testing is complete. In some instances, the cytopathology results are not clearly benign or malignant. This is called an indeterminate result.
Step 3: Genomic Testing
If your cytopathology result is indeterminate, Afirma Thyroid FNA Analysis will then evaluate the genes in your thyroid nodule cells. When Afirma genomic testing identifies a sample as benign—which it does in approximately half of indeterminate nodules—the chance of cancer is very low.1

Reference:1. Alexander EK, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705-715. 

Find a Doctor in your area that offers Afirma Testing.

Reduce wonder, worry, and wait.
Afirma test results will help your doctor confidently recommend a treatment plan, and you may avoid surgery without the need to repeat the biopsy.

Clinically Proven, Real World Tested Why Request Afirma Thyroid FNA Analysis?
Only Afirma Thyroid FNA Analysis combines the best of standard diagnostics with a genomic test. Our advanced science has helped thousands of patients avoid extra visits to the doctor and unnecessary surgeries.

The Science Behind Afirma In the past, up to 30% of regular thyroid fine needle aspiration (FNA) biopsy results would not clearly show whether the nodule is cancerous or not (called “indeterminate”). In most of these cases, surgery would be recommended to get a clear diagnosis and, in 70–80% of these patients the nodules turn out to be benign. For these people, surgery was not necessary. 

With the Afirma Solution, an indeterminate diagnosis isn’t the end of the story. It’s where our people and science step in to make a proven difference. 

Dedicated experts Obtaining a more definitive diagnosis requires skilled physicians who are dedicated. Thyroid Cytopathology Partners (TCP), the diagnostic partner of choice for Afirma, is an independent group of experienced cytopathologists. As one of the world’s largest cytopathology practices, they see a high volume of thyroid nodule samples and are experts in the field. Patient samples are read by one of TCP's specialists.

Latest genomic science Afirma Gene Expression Classifier was developed by experts in genomic science. Its results have been validated in a large national study conducted by leaders in the endocrinology field and published in the world-renowned New England Journal of Medicine.1

Clinically proven, real-world tested results Approximately half of the time, the Afirma GEC result is benign, giving doctors confidence that a thyroidectomy may not be needed. In the first four years of Afirma GEC availability, more than an estimated 15,000 nodules were reclassified from “indeterminate” to “benign,” helping many people avoid unnecessary surgeries.

In cases where Afirma GEC classifies a nodule as suspicious for cancer, it is still not certain that the nodule is malignant. The Afirma Solution continues to provide information that can make a difference in your story. We now offer two new tests designed to detect malignancy. From the original FNA biopsy, these two tests (Afirma BRAF and Afirma MTC) help guide physicians in choosing the best surgical option for those patients for whom surgery is appropriate. 

Talk to your doctor about the next chapter in your thyroid’s story. Find a doctor today.  
Or download information about Afirma.

1. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D,Diggans J, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705-715.